{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:34:22Z","timestamp":1772930062181,"version":"3.50.1"},"reference-count":82,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2022-NR070173"],"award-info":[{"award-number":["RS-2022-NR070173"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2022-NR073655"],"award-info":[{"award-number":["RS-2022-NR073655"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003662","name":"Korea Evaluation Institute of Industrial Technology","doi-asserted-by":"publisher","award":["RS-2025-16064070"],"award-info":[{"award-number":["RS-2025-16064070"]}],"id":[{"id":"10.13039\/501100003662","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Osteosarcoma, the most common malignant bone tumor in young individuals, often exhibits poor outcomes due to MDM2-mediated suppression of the p53 pathway. Whereas conventional MDM2 inhibitors block the p53\u2013MDM2 interaction but frequently induce compensatory MDM2 upregulation, proteolysis-targeting chimeras (PROTACs) directly degrade MDM2 and bypass this limitation. Here, we investigated the anticancer efficacy of two MDM2-targeting PROTAC compounds, CL0144 and CL0174, in osteosarcoma models. In Saos-2 and U2OS cells, both PROTACs efficiently induced MDM2 degradation, leading to activation of p53 or p73 signaling, increased reactive oxygen species production, apoptotic cell death, and marked reductions in viability. PROTAC treatment also significantly suppressed proliferation, colony formation, sphere formation, migration, and invasion. In vivo, xenograft assays demonstrated robust tumor growth inhibition following PROTAC administration. Collectively, these findings demonstrate that MDM2-targeting PROTACs exert strong antitumor effects by degrading MDM2 and disrupting downstream oncogenic pathways, supporting their potential as a promising therapeutic strategy for osteosarcoma.<\/jats:p>","DOI":"10.3390\/cells15050473","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:19:21Z","timestamp":1772720361000},"page":"473","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0833-8523","authenticated-orcid":false,"given":"Yeongji","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, CHA Bundang Medical Center, School of Medicine, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si 13488, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0186-5834","authenticated-orcid":false,"given":"Jin-Woo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Nowon Eulji Medical Center, Eulji University, Seoul 01830, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junwon","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhyeong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyeon","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wonji","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-715X","authenticated-orcid":false,"given":"Hyunju","family":"An","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, CHA Bundang Medical Center, School of Medicine, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si 13488, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinman","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Oral Microbiology and Immunology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul 08826, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-694X","authenticated-orcid":false,"given":"Minsup","family":"Kim","sequence":"additional","affiliation":[{"name":"TARS Scientific, Seoul 01717, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujin","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, CHA Bundang Medical Center, School of Medicine, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si 13488, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsu","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, CHA Bundang Medical Center, School of Medicine, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si 13488, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Il","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Ilsan Paik Hospital, Inje University, 170, Juhwa-ro, Ilsangeo-gu, Goyang-si 10380, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soonchul","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, CHA Bundang Medical Center, School of Medicine, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si 13488, Republic of Korea"},{"name":"SL Bio, Inc., 43, Beolmal-ro 30beon-gil, Bundang-gu, Seongnam-si 13503, Republic of Korea"},{"name":"Advanced College of Bio-Convergence Engineering, Ajou University, Suwon 16499, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1002324","DOI":"10.37349\/etat.2025.1002324","article-title":"Osteosarcoma: Current insights and advances","volume":"6","author":"Brar","year":"2025","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/cpr.12129","article-title":"Overexpression of metadherin mediates metastasis of osteosarcoma by regulating epithelial-mesenchymal transition","volume":"47","author":"Tang","year":"2014","journal-title":"Cell Prolif."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Saraf, A.J., Fenger, J.M., and Roberts, R.D. (2018). Osteosarcoma: Accelerating Progress Makes for a Hopeful Future. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00004"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hattinger, C.M., Patrizio, M.P., Fantoni, L., Casotti, C., Riganti, C., and Serra, M. (2021). Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. Cancers, 13.","DOI":"10.3390\/cancers13122878"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Lilienthal, I., and Herold, N. (2020). Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186885"},{"key":"ref_6","first-page":"244","article-title":"PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective","volume":"1","author":"Han","year":"2022","journal-title":"Acta Mater. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/BF01213553","article-title":"Alterations of the p53, Rb and MDM2 genes in osteosarcoma","volume":"122","author":"Miller","year":"1996","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","article-title":"p53 signaling in cancer progression and therapy","volume":"21","author":"Marei","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/CCO.0000000000001146","article-title":"MDM2 inhibitors in sarcomas: Results and next steps","volume":"37","author":"Tortorelli","year":"2025","journal-title":"Curr. Opin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Beloglazkina, A., Zyk, N., Majouga, A., and Beloglazkina, E. (2020). Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction. Molecules, 25.","DOI":"10.3390\/molecules25051211"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm400487c","article-title":"Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development","volume":"56","author":"Ding","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9630","DOI":"10.1021\/jm300969t","article-title":"Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction","volume":"55","author":"Zhuang","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1158\/1535-7163.MCT-24-0306","article-title":"KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors","volume":"24","author":"Chutake","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1073\/pnas.1620262114","article-title":"Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf(-\/-) mouse model","volume":"114","author":"Chapeau","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s41061-016-0089-0","article-title":"Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy","volume":"375","author":"Gupta","year":"2017","journal-title":"Top. Curr. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1541::AID-CNCR15>3.0.CO;2-Y","article-title":"p53 and MDM2 alterations in osteosarcomas","volume":"79","author":"Lonardo","year":"1997","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"eado6492","DOI":"10.1126\/sciadv.ado6492","article-title":"Mechanism of degrader-targeted protein ubiquitinability","volume":"10","author":"Crowe","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lee, J., Lee, Y., Jung, Y.M., Park, J.H., Yoo, H.S., and Park, J. (2022). Discovery of E3 Ligase Ligands for Target Protein Degradation. Molecules, 27.","DOI":"10.3390\/molecules27196515"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1039\/D2CS00387B","article-title":"Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders","volume":"51","author":"Diehl","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: A critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/bkcs.12921","article-title":"Discovery of novel benzosultam CRBN ligands","volume":"46","author":"Park","year":"2025","journal-title":"Bull. Korean Chem. Soc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/17460441.2019.1659242","article-title":"PROTACs- a game-changing technology","volume":"14","author":"Konstantinidou","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-Induced Protein Degradation with Photocaged PROTACs","volume":"141","author":"Xue","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1700247","DOI":"10.1002\/bies.201700247","article-title":"PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery","volume":"40","author":"Gu","year":"2018","journal-title":"Bioessays"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1021\/acs.biochem.9b00848","article-title":"PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance","volume":"59","author":"Sun","year":"2020","journal-title":"Biochemistry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e202300736","DOI":"10.1002\/cbic.202300736","article-title":"Design and Evaluation of PROTACs Targeting Acyl Protein Thioesterase 1","volume":"25","author":"Carvalho","year":"2024","journal-title":"ChemBioChem"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Nguyen, T.T., Kim, J.W., Choi, H.I., Maeng, H.J., and Koo, T.S. (2022). Development of an LC-MS\/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies. Molecules, 27.","DOI":"10.3390\/molecules27061977"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-targeting chimeras with reduced off-targets","volume":"16","author":"Nguyen","year":"2024","journal-title":"Nat. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1002\/mco2.290","article-title":"PROTACs: A novel strategy for cancer drug discovery and development","volume":"4","author":"Han","year":"2023","journal-title":"MedComm"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1021\/acs.biochem.1c00377","article-title":"Targeted Degradation of the Oncogenic Phosphatase SHP2","volume":"60","author":"Vemulapalli","year":"2021","journal-title":"Biochemistry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17691","DOI":"10.1039\/D4SC03555K","article-title":"Dual-ligand PROTACS mediate superior target protein degradation in vitro and therapeutic efficacy in vivo","volume":"15","author":"Chen","year":"2024","journal-title":"Chem. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e2500402","DOI":"10.1002\/smtd.202500402","article-title":"Proteolysis-Targeting Chimera (PROTAC): A Revolutionary Tool for Chemical Biology Research","volume":"9","author":"Pan","year":"2025","journal-title":"Small Methods"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mancarella, C., Morrione, A., and Scotlandi, K. (2023). PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216346"},{"key":"ref_35","first-page":"178","article-title":"Detection of p53 and MDM2 gene expression in osteosarcoma with biotin-labelled in situ","volume":"35","author":"Wang","year":"1997","journal-title":"Chin. J. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.4161\/cbt.21782","article-title":"Reporting of preclinical tumor-graft cancer therapeutic studies","volume":"13","author":"Sugar","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/MOP.0000000000000298","article-title":"Future directions in the treatment of osteosarcoma","volume":"28","author":"Bishop","year":"2016","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8945","DOI":"10.1074\/jbc.275.12.8945","article-title":"Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53","volume":"275","author":"Fang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e2415626","DOI":"10.1002\/advs.202415626","article-title":"Development of MDM2-Targeting PROTAC for Advancing Bone Regeneration","volume":"12","author":"Jeong","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: An emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sincere, N.I., Anand, K., Ashique, S., Yang, J., and You, C. (2023). PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies. Molecules, 28.","DOI":"10.3390\/molecules28104014"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Naito, M., Ohoka, N., Shibata, N., and Tsukumo, Y. (2019). Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs. Front. Chem., 7.","DOI":"10.3389\/fchem.2019.00849"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/acsptsci.2c00142","article-title":"Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation","volume":"5","author":"Ruffilli","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1158\/2159-8290.CD-23-0229","article-title":"MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation","volume":"13","author":"Peuget","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1006\/bbrc.1997.6216","article-title":"Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells","volume":"232","author":"Ishioka","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1038\/sj.onc.1202931","article-title":"p53-dependent apoptosis or growth arrest induced by different forms of radiation in U2OS cells: P21WAF1\/CIP1 repression in UV induced apoptosis","volume":"18","author":"Allan","year":"1999","journal-title":"Oncogene"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1101\/gad.1941710","article-title":"The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor","volume":"24","author":"Manfredi","year":"2010","journal-title":"Genes Dev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1128\/MCB.19.5.3257","article-title":"MDM2 suppresses p73 function without promoting p73 degradation","volume":"19","author":"Zeng","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/38298","article-title":"p73 is a simian [correction of human] p53-related protein that can induce apoptosis","volume":"389","author":"Jost","year":"1997","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.pharmtox.48.113006.094723","article-title":"Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: A novel approach for cancer therapy","volume":"49","author":"Shangary","year":"2009","journal-title":"Annu. Rev. Pharmacol Toxicol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/17460441003677725","article-title":"The dynamics of drug-target interactions: Drug-target residence time and its impact on efficacy and safety","volume":"5","author":"Copeland","year":"2010","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4161\/cc.3.4.801","article-title":"Small-molecule antagonists of p53-MDM2 binding: Research tools and potential therapeutics","volume":"3","author":"Vassilev","year":"2004","journal-title":"Cell Cycle"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6472","DOI":"10.1021\/ja800201j","article-title":"Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft","volume":"130","author":"Showalter","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9646","DOI":"10.1158\/0008-5472.CAN-06-0792","article-title":"Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma","volume":"66","author":"Speleman","year":"2006","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"19503","DOI":"10.1021\/acs.jmedchem.4c01818","article-title":"Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia","volume":"67","author":"Aguilar","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"26315","DOI":"10.1074\/jbc.M109.046904","article-title":"Nutlin-3 affects expression and function of retinoblastoma protein: Role of retinoblastoma protein in cellular response to nutlin-3","volume":"284","author":"Du","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/j.1460-2075.1993.tb05678.x","article-title":"mdm2 expression is induced by wild type p53 activity","volume":"12","author":"Barak","year":"1993","journal-title":"EMBO J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7218","DOI":"10.1021\/jacs.2c12809","article-title":"Ligation to Scavenging Strategy Enables On-Demand Termination of Targeted Protein Degradation","volume":"145","author":"Jin","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1021\/acs.jmedchem.8b00909","article-title":"Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression","volume":"62","author":"Li","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_63","first-page":"22","article-title":"Divergence to apoptosis from ROS induced cell cycle arrest: Effect of cadmium","volume":"663","author":"Chatterjee","year":"2009","journal-title":"Mutat. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1158\/0008-5472.CAN-12-2359","article-title":"Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer","volume":"72","author":"Ren","year":"2012","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/dna.2017.3962","article-title":"APTM, a Thiophene Heterocyclic Compound, Inhibits Human Colon Cancer HCT116 Cell Proliferation Through p53-Dependent Induction of Apoptosis","volume":"37","author":"Liao","year":"2018","journal-title":"DNA Cell Biol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Uehara, I., and Tanaka, N. (2018). Role of p53 in the Regulation of the Inflammatory Tumor Microenvironment and Tumor Suppression. Cancers, 10.","DOI":"10.3390\/cancers10070219"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1158\/0008-5472.CAN-18-2918","article-title":"MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53","volume":"79","author":"Hines","year":"2019","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1021\/jacs.1c00451","article-title":"Cancer Selective Target Degradation by Folate-Caged PROTACs","volume":"143","author":"Liu","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Murayama, T., and Gotoh, N. (2019). Patient-Derived Xenograft Models of Breast Cancer and Their Application. Cells, 8.","DOI":"10.3390\/cells8060621"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Rej, R.K., Allu, S.R., Roy, J., Acharyya, R.K., Kiran, I.N.C., Addepalli, Y., and Dhamodharan, V. (2024). Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs. Pharmaceuticals, 17.","DOI":"10.3390\/ph17040494"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","article-title":"Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"28502","DOI":"10.1021\/acsnano.4c09800","article-title":"Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment","volume":"18","author":"Wu","year":"2024","journal-title":"ACS Nano"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"23299","DOI":"10.1002\/anie.202107347","article-title":"Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer","volume":"60","author":"He","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/ijc.32662","article-title":"The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance","volume":"146","author":"Shi","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e2200195","DOI":"10.1002\/adhm.202200195","article-title":"Engineering Novel 3D Models to Recreate High-Grade Osteosarcoma and its Immune and Extracellular Matrix Microenvironment","volume":"11","author":"Pierrevelcin","year":"2022","journal-title":"Adv. Healthc. Mater."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1158\/0008-5472.CAN-08-3732","article-title":"Mdm2 affects genome stability independent of p53","volume":"69","author":"Bouska","year":"2009","journal-title":"Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1568009053332636","article-title":"MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy","volume":"5","author":"Rayburn","year":"2005","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.2147\/IJN.S448684","article-title":"Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy","volume":"19","author":"Song","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Vicente, A.T.S., and Salvador, J.A.R. (2022). MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911068"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e70011","DOI":"10.1002\/fsn3.70011","article-title":"Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons","volume":"13","author":"Ibrahim","year":"2025","journal-title":"Food Sci. Nutr."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/5\/473\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:15:21Z","timestamp":1772860521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/5\/473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":82,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cells15050473"],"URL":"https:\/\/doi.org\/10.3390\/cells15050473","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}